Liafensine (BMS-820836) is a
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by
Bristol-Myers Squibb for the treatment of
major depressive disorder.
Though it demonstrated comparable effectiveness to
escitalopram and
duloxetine in
phase II Phase II, Phase 2 or Phase Two may refer to:
Media
* Marvel Cinematic Universe: Phase Two, six American superhero films from 2013–2015
* ''Star Trek: Phase II'', an unrealized television series based on the characters of Gene Roddenberry's ''S ...
clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for
side effects as well as
potential for abuse.
Another clinical trial of liafensine began in 2022.
See also
*
Amitifadine
Amitifadine (developmental code names DOV-21,947, EB-1010) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) or so-called triple reuptake inhibitor (TRI) which is or was being developed by Euthymics Bioscience It was under de ...
*
Ansofaxine
References
Experimental antidepressants
Serotonin–norepinephrine–dopamine reuptake inhibitors
{{nervous-system-drug-stub